nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—AKR1C3—prostate cancer	0.332	0.851	CbGaD
Mefenamic acid—AKR1C3—Doxorubicin—prostate cancer	0.0699	0.223	CbGbCtD
Mefenamic acid—PTGS2—prostate cancer	0.0582	0.149	CbGaD
Mefenamic acid—CYP2C8—Nilutamide—prostate cancer	0.0361	0.115	CbGbCtD
Mefenamic acid—CYP2C8—Abiraterone—prostate cancer	0.0299	0.0952	CbGbCtD
Mefenamic acid—CYP2C9—Nilutamide—prostate cancer	0.0252	0.0802	CbGbCtD
Mefenamic acid—CYP2C9—Bicalutamide—prostate cancer	0.0252	0.0802	CbGbCtD
Mefenamic acid—CYP2C8—Cabazitaxel—prostate cancer	0.0221	0.0704	CbGbCtD
Mefenamic acid—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0193	0.0614	CbGbCtD
Mefenamic acid—PTGS2—Etoposide—prostate cancer	0.0166	0.053	CbGbCtD
Mefenamic acid—CYP2C9—Estrone—prostate cancer	0.0151	0.048	CbGbCtD
Mefenamic acid—PTGS1—Etoposide—prostate cancer	0.014	0.0447	CbGbCtD
Mefenamic acid—CYP2C8—Estradiol—prostate cancer	0.0124	0.0395	CbGbCtD
Mefenamic acid—CYP2C9—Capecitabine—prostate cancer	0.0114	0.0364	CbGbCtD
Mefenamic acid—CYP2C9—Estradiol—prostate cancer	0.00865	0.0276	CbGbCtD
Mefenamic acid—CYP2C8—Etoposide—prostate cancer	0.0081	0.0258	CbGbCtD
Mefenamic acid—AKR1C2—prostate gland—prostate cancer	0.00588	0.228	CbGeAlD
Mefenamic acid—AKR1C2—testis—prostate cancer	0.00259	0.101	CbGeAlD
Mefenamic acid—CYP2C9—urine—prostate cancer	0.00198	0.0769	CbGeAlD
Mefenamic acid—AKR1C2—lymph node—prostate cancer	0.00188	0.0729	CbGeAlD
Mefenamic acid—AKR1C3—prostate gland—prostate cancer	0.00184	0.0713	CbGeAlD
Mefenamic acid—AKR1C3—Podofilox—Etoposide—prostate cancer	0.00175	1	CbGdCrCtD
Mefenamic acid—AKR1C3—seminal vesicle—prostate cancer	0.00155	0.0603	CbGeAlD
Mefenamic acid—AKR1C3—urethra—prostate cancer	0.00123	0.0477	CbGeAlD
Mefenamic acid—AKR1C3—bone marrow—prostate cancer	0.000946	0.0367	CbGeAlD
Mefenamic acid—AKR1C3—testis—prostate cancer	0.000808	0.0314	CbGeAlD
Mefenamic acid—PTGS1—prostate gland—prostate cancer	0.000649	0.0252	CbGeAlD
Mefenamic acid—PTGS2—prostate gland—prostate cancer	0.000621	0.0241	CbGeAlD
Mefenamic acid—AKR1C3—lymph node—prostate cancer	0.000586	0.0228	CbGeAlD
Mefenamic acid—PTGS1—seminal vesicle—prostate cancer	0.000549	0.0213	CbGeAlD
Mefenamic acid—CYP2C8—renal system—prostate cancer	0.000546	0.0212	CbGeAlD
Mefenamic acid—PTGS2—seminal vesicle—prostate cancer	0.000525	0.0204	CbGeAlD
Mefenamic acid—Meclofenamic acid—AKR1C3—prostate cancer	0.000502	0.165	CrCbGaD
Mefenamic acid—PTGS1—epithelium—prostate cancer	0.000477	0.0185	CbGeAlD
Mefenamic acid—PTGS2—epithelium—prostate cancer	0.000456	0.0177	CbGeAlD
Mefenamic acid—PTGS1—renal system—prostate cancer	0.000443	0.0172	CbGeAlD
Mefenamic acid—PTGS2—renal system—prostate cancer	0.000423	0.0164	CbGeAlD
Mefenamic acid—PTGS2—urethra—prostate cancer	0.000416	0.0161	CbGeAlD
Mefenamic acid—CYP2C8—testis—prostate cancer	0.000353	0.0137	CbGeAlD
Mefenamic acid—Acetylsalicylic acid—TP53—prostate cancer	0.000341	0.112	CrCbGaD
Mefenamic acid—PTGS2—bone marrow—prostate cancer	0.00032	0.0124	CbGeAlD
Mefenamic acid—PTGS1—testis—prostate cancer	0.000286	0.0111	CbGeAlD
Mefenamic acid—PTGS1—lymph node—prostate cancer	0.000207	0.00805	CbGeAlD
Mefenamic acid—PTGS2—lymph node—prostate cancer	0.000198	0.0077	CbGeAlD
Mefenamic acid—Lumiracoxib—CYP2C19—prostate cancer	0.000181	0.0598	CrCbGaD
Mefenamic acid—Diclofenac—CYP2C18—prostate cancer	0.000176	0.058	CrCbGaD
Mefenamic acid—Floctafenine—PTGS2—prostate cancer	0.000175	0.0577	CrCbGaD
Mefenamic acid—Diclofenac—CXCL8—prostate cancer	0.000168	0.0555	CrCbGaD
Mefenamic acid—Ketoprofen—CXCL8—prostate cancer	0.000149	0.0492	CrCbGaD
Mefenamic acid—Tiaprofenic acid—PTGS2—prostate cancer	0.000113	0.0372	CrCbGaD
Mefenamic acid—Lumiracoxib—PTGS2—prostate cancer	0.000113	0.0372	CrCbGaD
Mefenamic acid—Nepafenac—PTGS2—prostate cancer	0.000107	0.0354	CrCbGaD
Mefenamic acid—Acetylsalicylic acid—CYP2C19—prostate cancer	0.000107	0.0353	CrCbGaD
Mefenamic acid—Niflumic Acid—PTGS2—prostate cancer	0.000101	0.0332	CrCbGaD
Mefenamic acid—Salsalate—PTGS2—prostate cancer	8.92e-05	0.0294	CrCbGaD
Mefenamic acid—Meclofenamic acid—PTGS2—prostate cancer	8.8e-05	0.029	CrCbGaD
Mefenamic acid—Diclofenac—CYP2E1—prostate cancer	7.97e-05	0.0263	CrCbGaD
Mefenamic acid—Diclofenac—CYP2C19—prostate cancer	7.89e-05	0.026	CrCbGaD
Mefenamic acid—Diclofenac—CYP1A1—prostate cancer	7.86e-05	0.0259	CrCbGaD
Mefenamic acid—Fenoprofen—PTGS2—prostate cancer	7.37e-05	0.0243	CrCbGaD
Mefenamic acid—Acetylsalicylic acid—PTGS2—prostate cancer	6.67e-05	0.022	CrCbGaD
Mefenamic acid—Salicylic acid—PTGS2—prostate cancer	5.49e-05	0.0181	CrCbGaD
Mefenamic acid—Diclofenac—CYP3A4—prostate cancer	5.02e-05	0.0165	CrCbGaD
Mefenamic acid—Diclofenac—PTGS2—prostate cancer	4.91e-05	0.0162	CrCbGaD
Mefenamic acid—Flurbiprofen—PTGS2—prostate cancer	4.81e-05	0.0159	CrCbGaD
Mefenamic acid—Diarrhoea—Mitoxantrone—prostate cancer	4.39e-05	0.000324	CcSEcCtD
Mefenamic acid—Dry mouth—Capecitabine—prostate cancer	4.38e-05	0.000324	CcSEcCtD
Mefenamic acid—Vomiting—Estradiol—prostate cancer	4.38e-05	0.000324	CcSEcCtD
Mefenamic acid—Agranulocytosis—Epirubicin—prostate cancer	4.38e-05	0.000323	CcSEcCtD
Mefenamic acid—Pneumonia—Doxorubicin—prostate cancer	4.37e-05	0.000323	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Etoposide—prostate cancer	4.36e-05	0.000322	CcSEcCtD
Mefenamic acid—Shock—Docetaxel—prostate cancer	4.36e-05	0.000322	CcSEcCtD
Mefenamic acid—Ketoprofen—PTGS2—prostate cancer	4.35e-05	0.0143	CrCbGaD
Mefenamic acid—Ill-defined disorder—Prednisone—prostate cancer	4.35e-05	0.000321	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Docetaxel—prostate cancer	4.34e-05	0.000321	CcSEcCtD
Mefenamic acid—Rash—Estradiol—prostate cancer	4.34e-05	0.000321	CcSEcCtD
Mefenamic acid—Drowsiness—Doxorubicin—prostate cancer	4.34e-05	0.000321	CcSEcCtD
Mefenamic acid—Dermatitis—Estradiol—prostate cancer	4.34e-05	0.000321	CcSEcCtD
Mefenamic acid—Anaemia—Prednisone—prostate cancer	4.33e-05	0.00032	CcSEcCtD
Mefenamic acid—Confusional state—Capecitabine—prostate cancer	4.33e-05	0.00032	CcSEcCtD
Mefenamic acid—Tachycardia—Docetaxel—prostate cancer	4.33e-05	0.00032	CcSEcCtD
Mefenamic acid—Headache—Estradiol—prostate cancer	4.31e-05	0.000319	CcSEcCtD
Mefenamic acid—Skin disorder—Docetaxel—prostate cancer	4.31e-05	0.000318	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	4.3e-05	0.000318	CcSEcCtD
Mefenamic acid—Oedema—Capecitabine—prostate cancer	4.29e-05	0.000317	CcSEcCtD
Mefenamic acid—Angioedema—Prednisone—prostate cancer	4.28e-05	0.000316	CcSEcCtD
Mefenamic acid—Renal failure—Doxorubicin—prostate cancer	4.27e-05	0.000315	CcSEcCtD
Mefenamic acid—Infection—Capecitabine—prostate cancer	4.27e-05	0.000315	CcSEcCtD
Mefenamic acid—Urticaria—Etoposide—prostate cancer	4.24e-05	0.000313	CcSEcCtD
Mefenamic acid—Haemoglobin—Epirubicin—prostate cancer	4.23e-05	0.000313	CcSEcCtD
Mefenamic acid—Stomatitis—Doxorubicin—prostate cancer	4.23e-05	0.000313	CcSEcCtD
Mefenamic acid—Jaundice—Doxorubicin—prostate cancer	4.23e-05	0.000313	CcSEcCtD
Mefenamic acid—Anorexia—Docetaxel—prostate cancer	4.23e-05	0.000312	CcSEcCtD
Mefenamic acid—Malaise—Prednisone—prostate cancer	4.23e-05	0.000312	CcSEcCtD
Mefenamic acid—Shock—Capecitabine—prostate cancer	4.22e-05	0.000312	CcSEcCtD
Mefenamic acid—Abdominal pain—Etoposide—prostate cancer	4.22e-05	0.000312	CcSEcCtD
Mefenamic acid—Body temperature increased—Etoposide—prostate cancer	4.22e-05	0.000312	CcSEcCtD
Mefenamic acid—Conjunctivitis—Doxorubicin—prostate cancer	4.22e-05	0.000312	CcSEcCtD
Mefenamic acid—Vertigo—Prednisone—prostate cancer	4.21e-05	0.000311	CcSEcCtD
Mefenamic acid—Hepatitis—Epirubicin—prostate cancer	4.21e-05	0.000311	CcSEcCtD
Mefenamic acid—Haemorrhage—Epirubicin—prostate cancer	4.21e-05	0.000311	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Capecitabine—prostate cancer	4.2e-05	0.000311	CcSEcCtD
Mefenamic acid—Syncope—Prednisone—prostate cancer	4.2e-05	0.000311	CcSEcCtD
Mefenamic acid—Tachycardia—Capecitabine—prostate cancer	4.19e-05	0.00031	CcSEcCtD
Mefenamic acid—Skin disorder—Capecitabine—prostate cancer	4.17e-05	0.000308	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Epirubicin—prostate cancer	4.16e-05	0.000307	CcSEcCtD
Mefenamic acid—Hypotension—Docetaxel—prostate cancer	4.14e-05	0.000306	CcSEcCtD
Mefenamic acid—Haematuria—Doxorubicin—prostate cancer	4.14e-05	0.000306	CcSEcCtD
Mefenamic acid—Urethral disorder—Epirubicin—prostate cancer	4.13e-05	0.000305	CcSEcCtD
Mefenamic acid—Loss of consciousness—Prednisone—prostate cancer	4.12e-05	0.000304	CcSEcCtD
Mefenamic acid—Anorexia—Capecitabine—prostate cancer	4.09e-05	0.000302	CcSEcCtD
Mefenamic acid—Nausea—Estradiol—prostate cancer	4.09e-05	0.000302	CcSEcCtD
Mefenamic acid—Vomiting—Mitoxantrone—prostate cancer	4.08e-05	0.000301	CcSEcCtD
Mefenamic acid—Convulsion—Prednisone—prostate cancer	4.06e-05	0.0003	CcSEcCtD
Mefenamic acid—Agranulocytosis—Doxorubicin—prostate cancer	4.05e-05	0.000299	CcSEcCtD
Mefenamic acid—Hypertension—Prednisone—prostate cancer	4.05e-05	0.000299	CcSEcCtD
Mefenamic acid—Rash—Mitoxantrone—prostate cancer	4.05e-05	0.000299	CcSEcCtD
Mefenamic acid—Dermatitis—Mitoxantrone—prostate cancer	4.04e-05	0.000299	CcSEcCtD
Mefenamic acid—Headache—Mitoxantrone—prostate cancer	4.02e-05	0.000297	CcSEcCtD
Mefenamic acid—Hypotension—Capecitabine—prostate cancer	4.01e-05	0.000297	CcSEcCtD
Mefenamic acid—Insomnia—Docetaxel—prostate cancer	4.01e-05	0.000296	CcSEcCtD
Mefenamic acid—Paraesthesia—Docetaxel—prostate cancer	3.98e-05	0.000294	CcSEcCtD
Mefenamic acid—Erythema multiforme—Epirubicin—prostate cancer	3.98e-05	0.000294	CcSEcCtD
Mefenamic acid—Anxiety—Prednisone—prostate cancer	3.98e-05	0.000294	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.96e-05	0.000293	CcSEcCtD
Mefenamic acid—Dyspnoea—Docetaxel—prostate cancer	3.95e-05	0.000292	CcSEcCtD
Mefenamic acid—Somnolence—Docetaxel—prostate cancer	3.94e-05	0.000291	CcSEcCtD
Mefenamic acid—Discomfort—Prednisone—prostate cancer	3.94e-05	0.000291	CcSEcCtD
Mefenamic acid—Tinnitus—Epirubicin—prostate cancer	3.93e-05	0.00029	CcSEcCtD
Mefenamic acid—Haemoglobin—Doxorubicin—prostate cancer	3.92e-05	0.000289	CcSEcCtD
Mefenamic acid—Dyspepsia—Docetaxel—prostate cancer	3.9e-05	0.000288	CcSEcCtD
Mefenamic acid—Haemorrhage—Doxorubicin—prostate cancer	3.9e-05	0.000288	CcSEcCtD
Mefenamic acid—Hepatitis—Doxorubicin—prostate cancer	3.9e-05	0.000288	CcSEcCtD
Mefenamic acid—Insomnia—Capecitabine—prostate cancer	3.88e-05	0.000287	CcSEcCtD
Mefenamic acid—Paraesthesia—Capecitabine—prostate cancer	3.86e-05	0.000285	CcSEcCtD
Mefenamic acid—Decreased appetite—Docetaxel—prostate cancer	3.86e-05	0.000285	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Doxorubicin—prostate cancer	3.85e-05	0.000284	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Docetaxel—prostate cancer	3.83e-05	0.000283	CcSEcCtD
Mefenamic acid—Asthenia—Etoposide—prostate cancer	3.83e-05	0.000283	CcSEcCtD
Mefenamic acid—Dyspnoea—Capecitabine—prostate cancer	3.83e-05	0.000283	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Prednisone—prostate cancer	3.83e-05	0.000283	CcSEcCtD
Mefenamic acid—Oedema—Prednisone—prostate cancer	3.83e-05	0.000283	CcSEcCtD
Mefenamic acid—Urethral disorder—Doxorubicin—prostate cancer	3.82e-05	0.000282	CcSEcCtD
Mefenamic acid—Nausea—Mitoxantrone—prostate cancer	3.81e-05	0.000282	CcSEcCtD
Mefenamic acid—Infection—Prednisone—prostate cancer	3.8e-05	0.000281	CcSEcCtD
Mefenamic acid—Constipation—Docetaxel—prostate cancer	3.79e-05	0.00028	CcSEcCtD
Mefenamic acid—Dyspepsia—Capecitabine—prostate cancer	3.78e-05	0.000279	CcSEcCtD
Mefenamic acid—Pruritus—Etoposide—prostate cancer	3.78e-05	0.000279	CcSEcCtD
Mefenamic acid—Shock—Prednisone—prostate cancer	3.76e-05	0.000278	CcSEcCtD
Mefenamic acid—Arrhythmia—Epirubicin—prostate cancer	3.76e-05	0.000278	CcSEcCtD
Mefenamic acid—Tachycardia—Prednisone—prostate cancer	3.73e-05	0.000276	CcSEcCtD
Mefenamic acid—Decreased appetite—Capecitabine—prostate cancer	3.73e-05	0.000276	CcSEcCtD
Mefenamic acid—Alopecia—Epirubicin—prostate cancer	3.72e-05	0.000275	CcSEcCtD
Mefenamic acid—Skin disorder—Prednisone—prostate cancer	3.72e-05	0.000275	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Capecitabine—prostate cancer	3.71e-05	0.000274	CcSEcCtD
Mefenamic acid—Mental disorder—Epirubicin—prostate cancer	3.69e-05	0.000273	CcSEcCtD
Mefenamic acid—Erythema multiforme—Doxorubicin—prostate cancer	3.68e-05	0.000272	CcSEcCtD
Mefenamic acid—Constipation—Capecitabine—prostate cancer	3.67e-05	0.000271	CcSEcCtD
Mefenamic acid—Feeling abnormal—Docetaxel—prostate cancer	3.65e-05	0.00027	CcSEcCtD
Mefenamic acid—Diarrhoea—Etoposide—prostate cancer	3.65e-05	0.00027	CcSEcCtD
Mefenamic acid—Anorexia—Prednisone—prostate cancer	3.65e-05	0.000269	CcSEcCtD
Mefenamic acid—Tinnitus—Doxorubicin—prostate cancer	3.63e-05	0.000268	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Docetaxel—prostate cancer	3.63e-05	0.000268	CcSEcCtD
Mefenamic acid—Flatulence—Epirubicin—prostate cancer	3.61e-05	0.000267	CcSEcCtD
Mefenamic acid—Tension—Epirubicin—prostate cancer	3.6e-05	0.000266	CcSEcCtD
Mefenamic acid—Nervousness—Epirubicin—prostate cancer	3.56e-05	0.000263	CcSEcCtD
Mefenamic acid—Feeling abnormal—Capecitabine—prostate cancer	3.54e-05	0.000261	CcSEcCtD
Mefenamic acid—Dizziness—Etoposide—prostate cancer	3.53e-05	0.000261	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Capecitabine—prostate cancer	3.51e-05	0.000259	CcSEcCtD
Mefenamic acid—Abdominal pain—Docetaxel—prostate cancer	3.51e-05	0.000259	CcSEcCtD
Mefenamic acid—Body temperature increased—Docetaxel—prostate cancer	3.51e-05	0.000259	CcSEcCtD
Mefenamic acid—Arrhythmia—Doxorubicin—prostate cancer	3.48e-05	0.000257	CcSEcCtD
Mefenamic acid—Insomnia—Prednisone—prostate cancer	3.46e-05	0.000256	CcSEcCtD
Mefenamic acid—Vision blurred—Epirubicin—prostate cancer	3.45e-05	0.000255	CcSEcCtD
Mefenamic acid—Alopecia—Doxorubicin—prostate cancer	3.44e-05	0.000254	CcSEcCtD
Mefenamic acid—Paraesthesia—Prednisone—prostate cancer	3.43e-05	0.000254	CcSEcCtD
Mefenamic acid—Mental disorder—Doxorubicin—prostate cancer	3.41e-05	0.000252	CcSEcCtD
Mefenamic acid—Urticaria—Capecitabine—prostate cancer	3.41e-05	0.000252	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Epirubicin—prostate cancer	3.4e-05	0.000251	CcSEcCtD
Mefenamic acid—Abdominal pain—Capecitabine—prostate cancer	3.39e-05	0.000251	CcSEcCtD
Mefenamic acid—Body temperature increased—Capecitabine—prostate cancer	3.39e-05	0.000251	CcSEcCtD
Mefenamic acid—Vomiting—Etoposide—prostate cancer	3.39e-05	0.000251	CcSEcCtD
Mefenamic acid—Anaemia—Epirubicin—prostate cancer	3.39e-05	0.00025	CcSEcCtD
Mefenamic acid—Dyspepsia—Prednisone—prostate cancer	3.37e-05	0.000249	CcSEcCtD
Mefenamic acid—Rash—Etoposide—prostate cancer	3.36e-05	0.000249	CcSEcCtD
Mefenamic acid—Dermatitis—Etoposide—prostate cancer	3.36e-05	0.000248	CcSEcCtD
Mefenamic acid—Headache—Etoposide—prostate cancer	3.34e-05	0.000247	CcSEcCtD
Mefenamic acid—Flatulence—Doxorubicin—prostate cancer	3.34e-05	0.000247	CcSEcCtD
Mefenamic acid—Tension—Doxorubicin—prostate cancer	3.33e-05	0.000246	CcSEcCtD
Mefenamic acid—Decreased appetite—Prednisone—prostate cancer	3.33e-05	0.000246	CcSEcCtD
Mefenamic acid—Malaise—Epirubicin—prostate cancer	3.31e-05	0.000244	CcSEcCtD
Mefenamic acid—Nervousness—Doxorubicin—prostate cancer	3.29e-05	0.000243	CcSEcCtD
Mefenamic acid—Vertigo—Epirubicin—prostate cancer	3.29e-05	0.000243	CcSEcCtD
Mefenamic acid—Syncope—Epirubicin—prostate cancer	3.29e-05	0.000243	CcSEcCtD
Mefenamic acid—Leukopenia—Epirubicin—prostate cancer	3.28e-05	0.000242	CcSEcCtD
Mefenamic acid—Constipation—Prednisone—prostate cancer	3.27e-05	0.000242	CcSEcCtD
Mefenamic acid—Palpitations—Epirubicin—prostate cancer	3.24e-05	0.000239	CcSEcCtD
Mefenamic acid—Loss of consciousness—Epirubicin—prostate cancer	3.22e-05	0.000238	CcSEcCtD
Mefenamic acid—Vision blurred—Doxorubicin—prostate cancer	3.2e-05	0.000236	CcSEcCtD
Mefenamic acid—Asthenia—Docetaxel—prostate cancer	3.18e-05	0.000235	CcSEcCtD
Mefenamic acid—Convulsion—Epirubicin—prostate cancer	3.18e-05	0.000235	CcSEcCtD
Mefenamic acid—Nausea—Etoposide—prostate cancer	3.17e-05	0.000234	CcSEcCtD
Mefenamic acid—Hypertension—Epirubicin—prostate cancer	3.16e-05	0.000234	CcSEcCtD
Mefenamic acid—Feeling abnormal—Prednisone—prostate cancer	3.15e-05	0.000233	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Doxorubicin—prostate cancer	3.15e-05	0.000233	CcSEcCtD
Mefenamic acid—Pruritus—Docetaxel—prostate cancer	3.14e-05	0.000232	CcSEcCtD
Mefenamic acid—Anaemia—Doxorubicin—prostate cancer	3.13e-05	0.000232	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Prednisone—prostate cancer	3.13e-05	0.000231	CcSEcCtD
Mefenamic acid—Anxiety—Epirubicin—prostate cancer	3.11e-05	0.00023	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.1e-05	0.000229	CcSEcCtD
Mefenamic acid—Discomfort—Epirubicin—prostate cancer	3.08e-05	0.000228	CcSEcCtD
Mefenamic acid—Asthenia—Capecitabine—prostate cancer	3.08e-05	0.000228	CcSEcCtD
Mefenamic acid—Malaise—Doxorubicin—prostate cancer	3.06e-05	0.000226	CcSEcCtD
Mefenamic acid—Dry mouth—Epirubicin—prostate cancer	3.05e-05	0.000226	CcSEcCtD
Mefenamic acid—Vertigo—Doxorubicin—prostate cancer	3.05e-05	0.000225	CcSEcCtD
Mefenamic acid—Syncope—Doxorubicin—prostate cancer	3.04e-05	0.000225	CcSEcCtD
Mefenamic acid—Urticaria—Prednisone—prostate cancer	3.04e-05	0.000225	CcSEcCtD
Mefenamic acid—Pruritus—Capecitabine—prostate cancer	3.04e-05	0.000224	CcSEcCtD
Mefenamic acid—Leukopenia—Doxorubicin—prostate cancer	3.04e-05	0.000224	CcSEcCtD
Mefenamic acid—Diarrhoea—Docetaxel—prostate cancer	3.03e-05	0.000224	CcSEcCtD
Mefenamic acid—Abdominal pain—Prednisone—prostate cancer	3.02e-05	0.000223	CcSEcCtD
Mefenamic acid—Body temperature increased—Prednisone—prostate cancer	3.02e-05	0.000223	CcSEcCtD
Mefenamic acid—Confusional state—Epirubicin—prostate cancer	3.02e-05	0.000223	CcSEcCtD
Mefenamic acid—Palpitations—Doxorubicin—prostate cancer	3e-05	0.000221	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Epirubicin—prostate cancer	2.99e-05	0.000221	CcSEcCtD
Mefenamic acid—Oedema—Epirubicin—prostate cancer	2.99e-05	0.000221	CcSEcCtD
Mefenamic acid—Loss of consciousness—Doxorubicin—prostate cancer	2.98e-05	0.00022	CcSEcCtD
Mefenamic acid—Infection—Epirubicin—prostate cancer	2.97e-05	0.00022	CcSEcCtD
Mefenamic acid—Shock—Epirubicin—prostate cancer	2.94e-05	0.000217	CcSEcCtD
Mefenamic acid—Convulsion—Doxorubicin—prostate cancer	2.94e-05	0.000217	CcSEcCtD
Mefenamic acid—Diarrhoea—Capecitabine—prostate cancer	2.94e-05	0.000217	CcSEcCtD
Mefenamic acid—Dizziness—Docetaxel—prostate cancer	2.93e-05	0.000217	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Epirubicin—prostate cancer	2.93e-05	0.000216	CcSEcCtD
Mefenamic acid—Hypertension—Doxorubicin—prostate cancer	2.93e-05	0.000216	CcSEcCtD
Mefenamic acid—Tachycardia—Epirubicin—prostate cancer	2.92e-05	0.000216	CcSEcCtD
Mefenamic acid—Skin disorder—Epirubicin—prostate cancer	2.91e-05	0.000215	CcSEcCtD
Mefenamic acid—Anxiety—Doxorubicin—prostate cancer	2.88e-05	0.000213	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.87e-05	0.000212	CcSEcCtD
Mefenamic acid—Discomfort—Doxorubicin—prostate cancer	2.85e-05	0.000211	CcSEcCtD
Mefenamic acid—Anorexia—Epirubicin—prostate cancer	2.85e-05	0.000211	CcSEcCtD
Mefenamic acid—Dizziness—Capecitabine—prostate cancer	2.84e-05	0.00021	CcSEcCtD
Mefenamic acid—Dry mouth—Doxorubicin—prostate cancer	2.82e-05	0.000209	CcSEcCtD
Mefenamic acid—Vomiting—Docetaxel—prostate cancer	2.82e-05	0.000208	CcSEcCtD
Mefenamic acid—Rash—Docetaxel—prostate cancer	2.8e-05	0.000207	CcSEcCtD
Mefenamic acid—Hypotension—Epirubicin—prostate cancer	2.8e-05	0.000207	CcSEcCtD
Mefenamic acid—Dermatitis—Docetaxel—prostate cancer	2.79e-05	0.000206	CcSEcCtD
Mefenamic acid—Confusional state—Doxorubicin—prostate cancer	2.79e-05	0.000206	CcSEcCtD
Mefenamic acid—Headache—Docetaxel—prostate cancer	2.78e-05	0.000205	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Doxorubicin—prostate cancer	2.77e-05	0.000205	CcSEcCtD
Mefenamic acid—Oedema—Doxorubicin—prostate cancer	2.77e-05	0.000205	CcSEcCtD
Mefenamic acid—Infection—Doxorubicin—prostate cancer	2.75e-05	0.000203	CcSEcCtD
Mefenamic acid—Asthenia—Prednisone—prostate cancer	2.74e-05	0.000203	CcSEcCtD
Mefenamic acid—Vomiting—Capecitabine—prostate cancer	2.73e-05	0.000202	CcSEcCtD
Mefenamic acid—Shock—Doxorubicin—prostate cancer	2.72e-05	0.000201	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Doxorubicin—prostate cancer	2.71e-05	0.0002	CcSEcCtD
Mefenamic acid—Rash—Capecitabine—prostate cancer	2.71e-05	0.0002	CcSEcCtD
Mefenamic acid—Pruritus—Prednisone—prostate cancer	2.71e-05	0.0002	CcSEcCtD
Mefenamic acid—Insomnia—Epirubicin—prostate cancer	2.71e-05	0.0002	CcSEcCtD
Mefenamic acid—Dermatitis—Capecitabine—prostate cancer	2.71e-05	0.0002	CcSEcCtD
Mefenamic acid—Tachycardia—Doxorubicin—prostate cancer	2.7e-05	0.0002	CcSEcCtD
Mefenamic acid—Headache—Capecitabine—prostate cancer	2.69e-05	0.000199	CcSEcCtD
Mefenamic acid—Skin disorder—Doxorubicin—prostate cancer	2.69e-05	0.000199	CcSEcCtD
Mefenamic acid—Paraesthesia—Epirubicin—prostate cancer	2.69e-05	0.000198	CcSEcCtD
Mefenamic acid—Dyspnoea—Epirubicin—prostate cancer	2.67e-05	0.000197	CcSEcCtD
Mefenamic acid—Somnolence—Epirubicin—prostate cancer	2.66e-05	0.000197	CcSEcCtD
Mefenamic acid—Anorexia—Doxorubicin—prostate cancer	2.64e-05	0.000195	CcSEcCtD
Mefenamic acid—Nausea—Docetaxel—prostate cancer	2.63e-05	0.000195	CcSEcCtD
Mefenamic acid—Dyspepsia—Epirubicin—prostate cancer	2.63e-05	0.000195	CcSEcCtD
Mefenamic acid—Diarrhoea—Prednisone—prostate cancer	2.62e-05	0.000193	CcSEcCtD
Mefenamic acid—Decreased appetite—Epirubicin—prostate cancer	2.6e-05	0.000192	CcSEcCtD
Mefenamic acid—Hypotension—Doxorubicin—prostate cancer	2.59e-05	0.000191	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Epirubicin—prostate cancer	2.58e-05	0.000191	CcSEcCtD
Mefenamic acid—Constipation—Epirubicin—prostate cancer	2.56e-05	0.000189	CcSEcCtD
Mefenamic acid—Nausea—Capecitabine—prostate cancer	2.55e-05	0.000188	CcSEcCtD
Mefenamic acid—Dizziness—Prednisone—prostate cancer	2.53e-05	0.000187	CcSEcCtD
Mefenamic acid—Insomnia—Doxorubicin—prostate cancer	2.5e-05	0.000185	CcSEcCtD
Mefenamic acid—Paraesthesia—Doxorubicin—prostate cancer	2.49e-05	0.000184	CcSEcCtD
Mefenamic acid—Dyspnoea—Doxorubicin—prostate cancer	2.47e-05	0.000182	CcSEcCtD
Mefenamic acid—Feeling abnormal—Epirubicin—prostate cancer	2.47e-05	0.000182	CcSEcCtD
Mefenamic acid—Somnolence—Doxorubicin—prostate cancer	2.46e-05	0.000182	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Epirubicin—prostate cancer	2.45e-05	0.000181	CcSEcCtD
Mefenamic acid—Dyspepsia—Doxorubicin—prostate cancer	2.44e-05	0.00018	CcSEcCtD
Mefenamic acid—Vomiting—Prednisone—prostate cancer	2.43e-05	0.00018	CcSEcCtD
Mefenamic acid—Rash—Prednisone—prostate cancer	2.41e-05	0.000178	CcSEcCtD
Mefenamic acid—Dermatitis—Prednisone—prostate cancer	2.41e-05	0.000178	CcSEcCtD
Mefenamic acid—Decreased appetite—Doxorubicin—prostate cancer	2.41e-05	0.000178	CcSEcCtD
Mefenamic acid—Headache—Prednisone—prostate cancer	2.4e-05	0.000177	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.39e-05	0.000177	CcSEcCtD
Mefenamic acid—Urticaria—Epirubicin—prostate cancer	2.38e-05	0.000176	CcSEcCtD
Mefenamic acid—Constipation—Doxorubicin—prostate cancer	2.37e-05	0.000175	CcSEcCtD
Mefenamic acid—Body temperature increased—Epirubicin—prostate cancer	2.36e-05	0.000175	CcSEcCtD
Mefenamic acid—Abdominal pain—Epirubicin—prostate cancer	2.36e-05	0.000175	CcSEcCtD
Mefenamic acid—Feeling abnormal—Doxorubicin—prostate cancer	2.28e-05	0.000169	CcSEcCtD
Mefenamic acid—Nausea—Prednisone—prostate cancer	2.27e-05	0.000168	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Doxorubicin—prostate cancer	2.26e-05	0.000167	CcSEcCtD
Mefenamic acid—Urticaria—Doxorubicin—prostate cancer	2.2e-05	0.000162	CcSEcCtD
Mefenamic acid—Abdominal pain—Doxorubicin—prostate cancer	2.19e-05	0.000162	CcSEcCtD
Mefenamic acid—Body temperature increased—Doxorubicin—prostate cancer	2.19e-05	0.000162	CcSEcCtD
Mefenamic acid—Asthenia—Epirubicin—prostate cancer	2.15e-05	0.000159	CcSEcCtD
Mefenamic acid—Pruritus—Epirubicin—prostate cancer	2.12e-05	0.000156	CcSEcCtD
Mefenamic acid—Diarrhoea—Epirubicin—prostate cancer	2.05e-05	0.000151	CcSEcCtD
Mefenamic acid—Asthenia—Doxorubicin—prostate cancer	1.99e-05	0.000147	CcSEcCtD
Mefenamic acid—Dizziness—Epirubicin—prostate cancer	1.98e-05	0.000146	CcSEcCtD
Mefenamic acid—Pruritus—Doxorubicin—prostate cancer	1.96e-05	0.000145	CcSEcCtD
Mefenamic acid—Vomiting—Epirubicin—prostate cancer	1.9e-05	0.000141	CcSEcCtD
Mefenamic acid—Diarrhoea—Doxorubicin—prostate cancer	1.89e-05	0.00014	CcSEcCtD
Mefenamic acid—Rash—Epirubicin—prostate cancer	1.89e-05	0.000139	CcSEcCtD
Mefenamic acid—Dermatitis—Epirubicin—prostate cancer	1.88e-05	0.000139	CcSEcCtD
Mefenamic acid—Headache—Epirubicin—prostate cancer	1.87e-05	0.000138	CcSEcCtD
Mefenamic acid—Dizziness—Doxorubicin—prostate cancer	1.83e-05	0.000135	CcSEcCtD
Mefenamic acid—Nausea—Epirubicin—prostate cancer	1.78e-05	0.000131	CcSEcCtD
Mefenamic acid—Vomiting—Doxorubicin—prostate cancer	1.76e-05	0.00013	CcSEcCtD
Mefenamic acid—Rash—Doxorubicin—prostate cancer	1.75e-05	0.000129	CcSEcCtD
Mefenamic acid—Dermatitis—Doxorubicin—prostate cancer	1.74e-05	0.000129	CcSEcCtD
Mefenamic acid—Headache—Doxorubicin—prostate cancer	1.73e-05	0.000128	CcSEcCtD
Mefenamic acid—Nausea—Doxorubicin—prostate cancer	1.64e-05	0.000121	CcSEcCtD
Mefenamic acid—CYP2C8—Metabolism—NCOA3—prostate cancer	3.21e-06	2.47e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—COMT—prostate cancer	3.2e-06	2.47e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CB—prostate cancer	3.2e-06	2.47e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTP1—prostate cancer	3.19e-06	2.46e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGF10—prostate cancer	3.18e-06	2.45e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—KRAS—prostate cancer	3.16e-06	2.43e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—EP300—prostate cancer	3.15e-06	2.43e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	3.15e-06	2.43e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTA1—prostate cancer	3.15e-06	2.43e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—SLC5A5—prostate cancer	3.14e-06	2.42e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ITPR1—prostate cancer	3.14e-06	2.42e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—HSD3B2—prostate cancer	3.12e-06	2.4e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTO1—prostate cancer	3.12e-06	2.4e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NAT2—prostate cancer	3.12e-06	2.4e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.08e-06	2.38e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CXCL8—prostate cancer	3.08e-06	2.37e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP2E1—prostate cancer	3.07e-06	2.37e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—HPGDS—prostate cancer	3.06e-06	2.36e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP2C19—prostate cancer	3.04e-06	2.35e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NQO1—prostate cancer	3.03e-06	2.34e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—KRAS—prostate cancer	3.03e-06	2.34e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TGFBR2—prostate cancer	3.02e-06	2.33e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1B—prostate cancer	3e-06	2.32e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	3e-06	2.31e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—TH—prostate cancer	2.99e-06	2.31e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP2C18—prostate cancer	2.99e-06	2.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—LRP2—prostate cancer	2.99e-06	2.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PLCB2—prostate cancer	2.99e-06	2.3e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ITPR1—prostate cancer	2.97e-06	2.29e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.97e-06	2.29e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ACHE—prostate cancer	2.97e-06	2.29e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTT1—prostate cancer	2.97e-06	2.29e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—TYMS—prostate cancer	2.96e-06	2.28e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP3A4—prostate cancer	2.96e-06	2.28e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CASP3—prostate cancer	2.94e-06	2.27e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL2—prostate cancer	2.94e-06	2.27e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP2A6—prostate cancer	2.94e-06	2.26e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—P4HB—prostate cancer	2.93e-06	2.26e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTM1—prostate cancer	2.93e-06	2.26e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.92e-06	2.25e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP1B1—prostate cancer	2.91e-06	2.24e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PIK3CA—prostate cancer	2.9e-06	2.24e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—LPL—prostate cancer	2.87e-06	2.22e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CCND1—prostate cancer	2.87e-06	2.21e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKR1C3—prostate cancer	2.86e-06	2.2e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SLC22A1—prostate cancer	2.85e-06	2.2e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PRKACB—prostate cancer	2.84e-06	2.19e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CTNNB1—prostate cancer	2.84e-06	2.19e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—AKT1—prostate cancer	2.83e-06	2.18e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	2.82e-06	2.17e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GGT1—prostate cancer	2.82e-06	2.17e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP17A1—prostate cancer	2.81e-06	2.17e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—prostate cancer	2.81e-06	2.16e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PIK3CA—prostate cancer	2.79e-06	2.15e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MMP9—prostate cancer	2.78e-06	2.15e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SULT2A1—prostate cancer	2.78e-06	2.14e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYP1A1—prostate cancer	2.78e-06	2.14e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NCOA1—prostate cancer	2.77e-06	2.14e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.77e-06	2.14e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1A—prostate cancer	2.77e-06	2.14e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PTEN—prostate cancer	2.77e-06	2.13e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ERCC2—prostate cancer	2.75e-06	2.12e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP19A1—prostate cancer	2.73e-06	2.11e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MED12—prostate cancer	2.73e-06	2.11e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—LPL—prostate cancer	2.72e-06	2.1e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GNG5—prostate cancer	2.71e-06	2.09e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PDGFRB—prostate cancer	2.7e-06	2.08e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NCOA2—prostate cancer	2.68e-06	2.07e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—RXRA—prostate cancer	2.64e-06	2.03e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—EP300—prostate cancer	2.64e-06	2.03e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NCOA3—prostate cancer	2.61e-06	2.01e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ERCC2—prostate cancer	2.61e-06	2.01e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—MTHFR—prostate cancer	2.59e-06	2e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IL6—prostate cancer	2.57e-06	1.98e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	2.57e-06	1.98e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.57e-06	1.98e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SRC—prostate cancer	2.56e-06	1.98e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—SLC5A5—prostate cancer	2.56e-06	1.97e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ERBB3—prostate cancer	2.55e-06	1.97e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGFR2—prostate cancer	2.55e-06	1.97e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—COMT—prostate cancer	2.54e-06	1.96e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PPARA—prostate cancer	2.54e-06	1.96e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTP1—prostate cancer	2.53e-06	1.95e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—VEGFA—prostate cancer	2.5e-06	1.93e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP2E1—prostate cancer	2.5e-06	1.92e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—HPGDS—prostate cancer	2.49e-06	1.92e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ITPR1—prostate cancer	2.49e-06	1.92e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP2C19—prostate cancer	2.48e-06	1.91e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—STAT3—prostate cancer	2.47e-06	1.91e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NQO1—prostate cancer	2.47e-06	1.9e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—IL6—prostate cancer	2.47e-06	1.9e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MTHFR—prostate cancer	2.45e-06	1.89e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.45e-06	1.89e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TERT—prostate cancer	2.45e-06	1.89e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—TH—prostate cancer	2.43e-06	1.88e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTT1—prostate cancer	2.42e-06	1.86e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ACHE—prostate cancer	2.42e-06	1.86e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.42e-06	1.86e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP3A4—prostate cancer	2.41e-06	1.86e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.39e-06	1.85e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP2A6—prostate cancer	2.39e-06	1.84e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CAV1—prostate cancer	2.39e-06	1.84e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.38e-06	1.84e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—AKT1—prostate cancer	2.37e-06	1.83e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP1B1—prostate cancer	2.37e-06	1.82e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—TYMS—prostate cancer	2.35e-06	1.81e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HIF1A—prostate cancer	2.34e-06	1.8e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PIK3CA—prostate cancer	2.33e-06	1.8e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTM1—prostate cancer	2.32e-06	1.79e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKR1C3—prostate cancer	2.32e-06	1.79e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PRKACB—prostate cancer	2.31e-06	1.78e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MYC—prostate cancer	2.3e-06	1.77e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TGFB1—prostate cancer	2.29e-06	1.77e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GGT1—prostate cancer	2.29e-06	1.77e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP17A1—prostate cancer	2.29e-06	1.76e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—LPL—prostate cancer	2.28e-06	1.76e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.28e-06	1.76e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—AKT1—prostate cancer	2.28e-06	1.76e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CAV1—prostate cancer	2.26e-06	1.74e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NCOA1—prostate cancer	2.26e-06	1.74e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.26e-06	1.74e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—EGFR—prostate cancer	2.25e-06	1.73e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP19A1—prostate cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP1A1—prostate cancer	2.2e-06	1.7e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ERCC2—prostate cancer	2.19e-06	1.69e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NCOA2—prostate cancer	2.18e-06	1.68e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CG—prostate cancer	2.17e-06	1.68e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—RXRA—prostate cancer	2.15e-06	1.66e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—BAD—prostate cancer	2.13e-06	1.64e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KRAS—prostate cancer	2.12e-06	1.64e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.09e-06	1.61e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SLC5A5—prostate cancer	2.08e-06	1.6e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—COMT—prostate cancer	2.07e-06	1.59e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—APC—prostate cancer	2.06e-06	1.59e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTP1—prostate cancer	2.06e-06	1.59e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—INS—prostate cancer	2.06e-06	1.59e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—MTHFR—prostate cancer	2.05e-06	1.58e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—IRS1—prostate cancer	2.04e-06	1.57e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EGF—prostate cancer	2.04e-06	1.57e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP2E1—prostate cancer	2.03e-06	1.57e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ITPR1—prostate cancer	2.03e-06	1.56e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CREBBP—prostate cancer	2.02e-06	1.55e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PPARA—prostate cancer	2.02e-06	1.55e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NQO1—prostate cancer	2.01e-06	1.55e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.99e-06	1.54e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—TH—prostate cancer	1.98e-06	1.53e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—GSK3B—prostate cancer	1.98e-06	1.53e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.97e-06	1.52e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP3A4—prostate cancer	1.96e-06	1.51e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CA—prostate cancer	1.95e-06	1.5e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—INS—prostate cancer	1.95e-06	1.5e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.95e-06	1.5e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP1B1—prostate cancer	1.93e-06	1.48e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—TYMS—prostate cancer	1.91e-06	1.48e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CD—prostate cancer	1.91e-06	1.47e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CREBBP—prostate cancer	1.91e-06	1.47e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—AKT1—prostate cancer	1.91e-06	1.47e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CAV1—prostate cancer	1.9e-06	1.46e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTM1—prostate cancer	1.89e-06	1.46e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—prostate cancer	1.89e-06	1.46e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GGT1—prostate cancer	1.87e-06	1.44e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—LPL—prostate cancer	1.86e-06	1.43e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NCOA1—prostate cancer	1.84e-06	1.42e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MAP2K1—prostate cancer	1.82e-06	1.41e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CD—prostate cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP19A1—prostate cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NOS3—prostate cancer	1.81e-06	1.39e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.79e-06	1.38e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—SERPINE1—prostate cancer	1.79e-06	1.38e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ERCC2—prostate cancer	1.78e-06	1.37e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—RXRA—prostate cancer	1.75e-06	1.35e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGF2—prostate cancer	1.73e-06	1.34e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL6—prostate cancer	1.73e-06	1.33e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CG—prostate cancer	1.73e-06	1.33e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NOS3—prostate cancer	1.71e-06	1.32e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.7e-06	1.31e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—COMT—prostate cancer	1.68e-06	1.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTP1—prostate cancer	1.68e-06	1.29e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—MTHFR—prostate cancer	1.67e-06	1.29e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CB—prostate cancer	1.67e-06	1.28e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—JAK2—prostate cancer	1.66e-06	1.28e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTGS2—prostate cancer	1.65e-06	1.27e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ITPR1—prostate cancer	1.65e-06	1.27e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PPARA—prostate cancer	1.64e-06	1.26e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—INS—prostate cancer	1.63e-06	1.26e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MDM2—prostate cancer	1.62e-06	1.25e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.62e-06	1.25e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CREBBP—prostate cancer	1.6e-06	1.23e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ERBB2—prostate cancer	1.6e-06	1.23e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—AKT1—prostate cancer	1.59e-06	1.23e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CB—prostate cancer	1.58e-06	1.22e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—TYMS—prostate cancer	1.56e-06	1.2e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CAV1—prostate cancer	1.54e-06	1.19e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTM1—prostate cancer	1.54e-06	1.19e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CD—prostate cancer	1.52e-06	1.17e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—LPL—prostate cancer	1.51e-06	1.17e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1B—prostate cancer	1.48e-06	1.14e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.47e-06	1.14e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.46e-06	1.13e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ERCC2—prostate cancer	1.45e-06	1.12e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTEN—prostate cancer	1.44e-06	1.11e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NOS3—prostate cancer	1.43e-06	1.1e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.4e-06	1.08e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CTNNB1—prostate cancer	1.4e-06	1.08e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—EP300—prostate cancer	1.37e-06	1.06e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1A—prostate cancer	1.37e-06	1.05e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PTEN—prostate cancer	1.36e-06	1.05e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MTHFR—prostate cancer	1.36e-06	1.05e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PPARA—prostate cancer	1.33e-06	1.03e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—INS—prostate cancer	1.33e-06	1.03e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CB—prostate cancer	1.32e-06	1.02e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CREBBP—prostate cancer	1.3e-06	1e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EP300—prostate cancer	1.3e-06	1e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—SRC—prostate cancer	1.27e-06	9.76e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CAV1—prostate cancer	1.25e-06	9.68e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.23e-06	9.52e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—STAT3—prostate cancer	1.22e-06	9.41e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.2e-06	9.25e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NOS3—prostate cancer	1.17e-06	8.99e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.14e-06	8.81e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PTEN—prostate cancer	1.14e-06	8.81e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MYC—prostate cancer	1.13e-06	8.75e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TGFB1—prostate cancer	1.13e-06	8.72e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EGFR—prostate cancer	1.11e-06	8.55e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—EP300—prostate cancer	1.09e-06	8.41e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—INS—prostate cancer	1.08e-06	8.34e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.08e-06	8.3e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTGS2—prostate cancer	1.07e-06	8.22e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CREBBP—prostate cancer	1.06e-06	8.17e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KRAS—prostate cancer	1.05e-06	8.08e-06	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CA—prostate cancer	1.02e-06	7.83e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CD—prostate cancer	1e-06	7.75e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CA—prostate cancer	9.63e-07	7.42e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NOS3—prostate cancer	9.49e-07	7.32e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTEN—prostate cancer	9.3e-07	7.17e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—EP300—prostate cancer	8.87e-07	6.84e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CB—prostate cancer	8.76e-07	6.75e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTGS2—prostate cancer	8.68e-07	6.69e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—IL6—prostate cancer	8.53e-07	6.57e-06	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKT1—prostate cancer	8.3e-07	6.4e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CA—prostate cancer	8.06e-07	6.22e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKT1—prostate cancer	7.87e-07	6.06e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTEN—prostate cancer	7.57e-07	5.84e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—EP300—prostate cancer	7.22e-07	5.57e-06	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKT1—prostate cancer	6.59e-07	5.08e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CA—prostate cancer	6.56e-07	5.06e-06	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKT1—prostate cancer	5.36e-07	4.13e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CA—prostate cancer	5.34e-07	4.12e-06	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKT1—prostate cancer	4.36e-07	3.36e-06	CbGpPWpGaD
